KRON has been successfully added to your Stock Email Alerts list.
You can manage your stock email alerts here.
KRON has been removed from your Stock Email Alerts list.
Please enter Portfolio Name for new portfolio.
In calculating the Net Current Asset Value (NCAV), Benjamin Graham means a company's current assets (such as cash, marketable securities, and inventories) minus its total liabilities (including preferred stock, minority interest, and long-term debt).
Kronos Bio's net current asset value per share for the quarter that ended in Mar. 2024 was $1.87.
The historical rank and industry rank for Kronos Bio's Net Current Asset Value or its related term are showing as below:
During the past 6 years, the highest Price-to-Net-Current-Asset-Value Ratio of Kronos Bio was 4.39. The lowest was 0.40. And the median was 0.90.
The historical data trend for Kronos Bio's Net Current Asset Value can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Kronos Bio Annual Data | |||||||||||||||
Trend | Dec18 | Dec19 | Dec20 | Dec21 | Dec22 | Dec23 | |||||||||
Net Current Asset Value | Get a 7-Day Free Trial | -1.15 | 6.90 | 5.41 | 3.40 | 2.11 |
Kronos Bio Quarterly Data | ||||||||||||||||||||
Jun19 | Sep19 | Dec19 | Mar20 | Jun20 | Sep20 | Dec20 | Mar21 | Jun21 | Sep21 | Dec21 | Mar22 | Jun22 | Sep22 | Dec22 | Mar23 | Jun23 | Sep23 | Dec23 | Mar24 | |
Net Current Asset Value | Get a 7-Day Free Trial | 2.94 | 2.87 | 2.27 | 2.11 | 1.87 |
For the Biotechnology subindustry, Kronos Bio's Price-to-Net-Current-Asset-Value, along with its competitors' market caps and Price-to-Net-Current-Asset-Value data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
For the Biotechnology industry and Healthcare sector, Kronos Bio's Price-to-Net-Current-Asset-Value distribution charts can be found below:
* The bar in red indicates where Kronos Bio's Price-to-Net-Current-Asset-Value falls into.
Kronos Bio's Net Current Asset Value (NCAV) per share for the fiscal year that ended in Dec. 2023 is calculated as
Net Current Asset Value Per Share | (A: Dec. 2023 ) | ||||||||
= | (Total Current Assets | - | Total Liabilities | - | Minority Interest | - | Preferred Stock) | / | Shares Outstanding (EOP) |
= | (178.778 | - | 54.201 | - | 0 | - | 0) | / | 58.946 |
= | 2.11 |
Kronos Bio's Net Current Asset Value (NCAV) per share for the quarter that ended in Mar. 2024 is calculated as
Net Current Asset Value Per Share | (Q: Mar. 2024 ) | ||||||||
= | (Total Current Assets | - | Total Liabilities | - | Minority Interest | - | Preferred Stock) | / | Shares Outstanding (EOP) |
= | (158.359 | - | 46.011 | - | 0 | - | 0) | / | 60.089 |
= | 1.87 |
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Kronos Bio (NAS:KRON) Net Current Asset Value Explanation
Benjamin Graham first discussed net current asset value (NCAV) in the 1934 edition of "Security Analysis", which he coauthored with David Dodd. In the book, (net) current asset value is defined as:" current assets alone, minus all liabilities and claims ahead of the issue."
The common definition of NCAV is: NCAV = current assets – [total liabilities + minority interest + preferred stock]
Net current assets exclude not only the intangible assets but also the fixed and miscellaneous assets. In addition, Graham believed that preferred stock belongs on the liability side of the balance sheet, not as part of capital and surplus. In "Security Analysis", preferred stock is dubbed "an imperfect creditorship position" that is best placed on the balance sheet alongside funded debt.
One research study, covering the years 1970 through 1983 showed that portfolios picked at the beginning of each year, and held for one year, returned 29.4 percent, on average, over the 13-year period, compared to 11.5 percent for the S&P 500 Index. Other studies of Grahams strategy produced similar results.
Benjamin Graham looked for companies whose market values were less than two-thirds of their Net-Net Working Capital. They are collected under our Net-Net screener.
Thank you for viewing the detailed overview of Kronos Bio's Net Current Asset Value provided by GuruFocus.com. Please click on the following links to see related term pages.
Jorge Dimartino | officer: Chief Medical Officer & VP | C/O KRONOS BIO, INC., 1300 S, SAN MATEO CA 94402 |
Christopher Dinsmore | officer: Chief Scientific Officer | C/O KRONOS BIO, INC., 1300 EL CAMINO REAL, STE. 300, SAN MATEO CA 94402 |
Barbara Kosacz | officer: COO & General Counsel | 3175 HANOVER STREET, PALO ALTO CA 94304 |
Norbert W Bischofberger | director, 10 percent owner, officer: President & CEO | 333 LAKESIDE DR, C/O GILEAD SCIENCES, INC., FOSTER CITY CA 94404 |
Sandra A. Gardiner | officer: Interim CFO | CUTERA, INC., 3240 BAYSHORE BOULEVARD, BRISBANE CA 94005 |
Yasir B. Al-wakeel | officer: Chief Financial Officer | MERRIMACK PHARMACEUTICALS, INC., ONE KENDALL SQUARE, SUITE B7201, CAMBRIDGE MA 02139 |
Roger D Dansey | director | 21823 30TH DRIVE SE, BOTHELL WA 98021 |
Katherine V Stultz | director | C/O GRAPHITE BIO, INC., 279 EAST GRAND AVENUE, SUITE 430, SOUTH SAN FRANCISCO CA 94080 |
Backer Marianne De | director | 177 E COLORADO BLVD, SUITE 700, PASADENA CA 91105 |
Roshawn A. Blunt | director | 11682 EL CAMINO REAL STE 300, SAN DIEGO CA 92130 |
Jakob Loven | director | C/O ARVINAS, INC., 5 SCIENCE PARK, 395 WINCHESTER AVENUE, NEW HAVEN CT 06511 |
Taiyin Yang | director | 2631 HANOVER STREET, PALO ALTO CA 94304 |
Otello Stampacchia | director, 10 percent owner | 888 BOYLSTON ST., SUITE 1111, BOSTON MA 02199 |
John C Martin | director | 333 LAKESIDE DRIVE, FOSTER CITY X1 94404 |
Elena Ridloff | director | C/O ACADIA PHARMACEUTICALS INC., 12830 EL CAMINO REAL, SUITE 400, SAN DIEGO CA 92130 |
From GuruFocus
By Marketwired • 08-17-2023
By Value_Insider Value_Insider • 11-22-2022
By PurpleRose PurpleRose • 07-11-2022
By Marketwired • 11-02-2023
By GuruFocusNews GuruFocusNews • 07-01-2022
By Value_Insider Value_Insider • 12-11-2022
By Value_Insider Value_Insider • 12-07-2022
By PurpleRose PurpleRose • 08-16-2022
By Marketwired • 11-02-2023
By GuruFocusNews GuruFocusNews • 07-10-2022
Disclaimers: GuruFocus.com is not operated by a broker or a dealer. It has an affiliated registered investment adviser, which serves as the subadviser to an exchange traded fund. This investment adviser does not provide advice to individual investors. Under no circumstances does any information posted on GuruFocus.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The individuals or entities selected as "gurus" may buy and sell securities before and after any particular article and report and information herein is published, with respect to the securities discussed in any article and report posted herein. Gurus may be added or dropped from the GuruFocus site at any time. In no event shall GuruFocus.com be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on GuruFocus.com, or relating to the use of, or inability to use, GuruFocus.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. The gurus listed in this website are not affiliated with GuruFocus.com, LLC. Stock quotes provided by InterActive Data. Fundamental company data provided by Morningstar, updated daily.